Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GenomeDia

Financiado

Cerrado

GenomeDia a personalized medicine tool for diabetes

Diabetes Mellitus affects nearly 600 million people worldwide. It is a major cause of premature death, blindness, end stage kidney disease, and limb amputation. However, it is not a single disease. Most patients are catalogued as... ver más

31/01/2026

FUNDACIO PRIVADA C...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

FUNDACIO PRIVADA CENTRE DE REGULACIO GENOMICA Otras actividades deportivas asociacion

TRL 4-5 | 100K€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-06-06

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FUNDACIO PRIVADA CENTRE DE R...

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 19 meses Fecha Inicio: 2024-06-06
Fecha Fin: 2026-01-31

Líder del proyecto

FUNDACIO PRIVADA CENTRE DE REGULACIO GENOMICA Otras actividades deportivas asociacion

TRL 4-5 | 100K€

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Diabetes Mellitus affects nearly 600 million people worldwide. It is a major cause of premature death, blindness, end stage kidney disease, and limb amputation. However, it is not a single disease. Most patients are catalogued as type 2 diabetes, which is itself highly heterogeneous, while others have autoimmune type 1 diabetes. Genetic testing is currently able to define the precise cause of diabetes in a small group of young patients, although the categorization of diabetes subtypes is in most cases largely based on clinical judgement, rather than on specific tests. It is known, however, that the classification of diabetes subtypes has major implications for treatment. The emergence of whole genome sequencing in clinical practice provides new opportunities for classification of diabetes subtypes, but also entails major challenges such as the interpretation of non protein-coding variants. The recently funded ERC project DecodeDiabetes analyzed sequences from nearly 1500 young patients who had typical features of genetic forms of diabetes, but negative genetic tests in specialized genetic diagnostic laboratories. This study revealed different groups of genetic variants that cause diabetes in young patients with diabetes. It also developed approaches that leverage regulatory genomic knowledge to define noncoding genetic defects underlying human disease. The current proposal aims to compile new findings with existing knowledge, and to build a genetic interpretation solution to subcategorize young patients with diabetes. It will then validate this tool in patient cohorts. This proposal can thus translate fundamental knowledge derived from the ERC-funded Decode Diabetes project into applications whose valorization can bridge the gap to market and provide added value for society.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores